Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Debio 1562M

Next Previous
Drug Profile

Debio 1562M

Alternative Names: Debio-1562M

Latest Information Update: 27 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Debiopharm
  • Class Antineoplastics; Biological toxins; Drug conjugates; Immunoconjugates; Immunoglobulins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia

Most Recent Events

  • 25 Apr 2025 Pharmacodynamics and adverse event data from the preclinical trial in Acute myeloid leukaemia presented at the 116th Annual Meeting of the American Association for Cancer Research 2025 (AACR -2025)
  • 09 Dec 2023 Safety and pharmacodynamic data from preclinical studies in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 24 Jul 2023 Debiopharm plans a phase I/II trial for Acute myeloid leukemia (Second line therapy or greater) in May 2025 (NCT06969430) (EUDRACT2024-519610-32)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top